Plain-English translation of NCT06911710 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing CAR-T cell therapy, a treatment that uses your own immune cells that have been engineered in a laboratory to recognize and attack cancer cells. Researchers are studying whether this medication is safe and how well it works in patients with blood cancers—such as lymphoma, leukemia, and myeloma—that have returned or stopped responding to standard treatments.
Patients with blood cancers that don't respond to chemotherapy or come back after treatment have very limited options. This medication offers a new approach by harnessing the body's own immune system to fight these hard-to-treat cancers.
You likely qualify if…
You likely don't qualify if…
You will receive an infusion of the engineered immune cells, likely at a hospital or specialized treatment center. The trial uses a careful step-by-step approach to find the safest and most effective dose, meaning earlier participants receive lower doses and later participants may receive higher doses based on safety results. You will have regular visits for blood tests, imaging scans, and check-ups to monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China